Explore

Trendline Trendline
Incyte to Present Key Hematology and Oncology Data at EHA 2026 Congress

Incyte to Present Key Hematology and Oncology Data at EHA 2026 Congress

Incyte to Present Key Hematology and Oncology Data at EHA 2026 Congress
Trendline Trendline
Curis Reports First Quarter 2026 Financial Results Amid Ongoing Clinical Trials

Curis Reports First Quarter 2026 Financial Results Amid Ongoing Clinical Trials

Curis Reports First Quarter 2026 Financial Results Amid Ongoing Clinical Trials
Trendline Trendline
Partner Therapeutics Gains FDA Approval for Bizengri in Treating Advanced Cholangiocarcinoma

Partner Therapeutics Gains FDA Approval for Bizengri in Treating Advanced Cholangiocarcinoma

Partner Therapeutics Gains FDA Approval for Bizengri in Treating Advanced Cholangiocarcinoma
Trendline Trendline
Agenus Inc Reports Significant Revenue Growth and Profit in Q1 2026

Agenus Inc Reports Significant Revenue Growth and Profit in Q1 2026

Agenus Inc Reports Significant Revenue Growth and Profit in Q1 2026
Trendline Trendline
Partner Therapeutics Gains FDA Approval for Bizengri, Offering New Hope for Cholangiocarcinoma Patients

Partner Therapeutics Gains FDA Approval for Bizengri, Offering New Hope for Cholangiocarcinoma Patients

Partner Therapeutics Gains FDA Approval for Bizengri, Offering New Hope for Cholangiocarcinoma Patients
Trendline Trendline
Novo Nordisk's High-Dose Wegovy Shows Significant Weight Loss in STEP UP Trial

Novo Nordisk's High-Dose Wegovy Shows Significant Weight Loss in STEP UP Trial

Novo Nordisk's High-Dose Wegovy Shows Significant Weight Loss in STEP UP Trial
Trendline Trendline
Zai Lab Secures FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Cancers

Zai Lab Secures FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Cancers

Zai Lab Secures FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Cancers
Trendline Trendline
Agenus Advances BOT+BAL Immunotherapy with Phase 3 Trial and Strategic Collaboration

Agenus Advances BOT+BAL Immunotherapy with Phase 3 Trial and Strategic Collaboration

Agenus Advances BOT+BAL Immunotherapy with Phase 3 Trial and Strategic Collaboration
Trendline Trendline
Agenus Advances BOT+BAL Immunotherapy with Phase 3 Trial and Strategic Collaborations

Agenus Advances BOT+BAL Immunotherapy with Phase 3 Trial and Strategic Collaborations

Agenus Advances BOT+BAL Immunotherapy with Phase 3 Trial and Strategic Collaborations
Trendline Trendline
Verastem Oncology to Present at Key Investor Conferences in May 2026

Verastem Oncology to Present at Key Investor Conferences in May 2026

Verastem Oncology to Present at Key Investor Conferences in May 2026
Trendline Trendline
Halia Therapeutics to Present Phase 2 Ofirnoflast Data and Appoints New Chief Medical Officer

Halia Therapeutics to Present Phase 2 Ofirnoflast Data and Appoints New Chief Medical Officer

Halia Therapeutics to Present Phase 2 Ofirnoflast Data and Appoints New Chief Medical Officer
Trendline Trendline
Anixa Biosciences Reports Positive Survival Data from Phase 1 Trial of Lira-cel Ovarian Cancer Therapy

Anixa Biosciences Reports Positive Survival Data from Phase 1 Trial of Lira-cel Ovarian Cancer Therapy

Anixa Biosciences Reports Positive Survival Data from Phase 1 Trial of Lira-cel Ovarian Cancer Therapy